Expert opinion on drug delivery最新文献

Advancing transdermal drug delivery: integration of microneedle technology and iontophoresis for enhanced therapeutic outcomes. 推进经皮给药：微针技术和离子透入的整合以提高治疗效果。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-05-05 DOI: 10.1080/17425247.2026.2667834

Meheli Ghosh, Amruta A Dandekar, Ajay K Banga, Ashana Puri

{"title":"Advancing transdermal drug delivery: integration of microneedle technology and iontophoresis for enhanced therapeutic outcomes.","authors":"Meheli Ghosh, Amruta A Dandekar, Ajay K Banga, Ashana Puri","doi":"10.1080/17425247.2026.2667834","DOIUrl":"10.1080/17425247.2026.2667834","url":null,"abstract":"Introduction: Integrated microneedle-iontophoresis (MN-ITP) systems are emerging as a promising approach to improve transdermal drug delivery. These work by dual effect, such as mechanical disruption of the stratum corneum along with electrically driven transport. This approach has gained increasing attention for both small molecules and macromolecules, offering the possibility of controlled, minimally invasive administration with improved pharmacokinetic outcomes compared with conventional methods.Areas covered: This review highlights MN-ITP strategies for transdermal delivery, based on a targeted search of major databases, patents, and FDA guidance (1984-2026), emphasizing therapeutic applications since 2015. Different MN-ITP device designs investigated for small molecules as well as larger therapeutics, such as peptides, proteins, and vaccines have been discussed. The review focuses on how device design, drug properties, and delivery performance influence outcomes, and compares integrated simultaneous systems with sequential MN-ITP approaches.Expert opinion/commentary: Current evidence indicates that integrated MN-ITP systems can enhance transdermal delivery, though outcomes depend on drug properties, loading strategies, and electrical parameters. Combined systems often act complementarily rather than uniformly superior, highlighting the need for rational, drug-specific design. Future work should focus on wearable and closed-loop platforms, optimized current density and MN architecture, and clinical translation.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-20"},"PeriodicalIF":5.4,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

User acceptability and ease of use of the MedRing, a new personalized vaginal drug delivery and monitoring device. 用户可接受性和易用性的MedRing，一种新的个性化阴道给药和监测装置。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-05-01 Epub Date: 2026-01-24 DOI: 10.1080/17425247.2026.2619095

Joggem Veen, Marian Engberts, Maarten Wiegerinck, Huub van der Vaart

{"title":"User acceptability and ease of use of the MedRing, a new personalized vaginal drug delivery and monitoring device.","authors":"Joggem Veen, Marian Engberts, Maarten Wiegerinck, Huub van der Vaart","doi":"10.1080/17425247.2026.2619095","DOIUrl":"10.1080/17425247.2026.2619095","url":null,"abstract":"Background: The MedRing is an innovative, flexible vaginal ring that, unlike other rings, allows personalized drug administration and monitoring. This study evaluated its user acceptability and ease of use.Research design and methods: This was an exploratory, prospective, open-label, interventional, multicenter study. Twenty-one women (25 - 75 years) used the dummy/placebo MedRing for three weeks, with insertions/removals on day 1 and after weeks 1 and 3. Participants scored design, ease of self-insertion/removal, wearing comfort, and potential future use. They also kept a daily diary, rating comfort on a 10-point scale (1 = intolerable, 10 = no problem). In addition, physicians rated ease of use and complications on a 5-point scale (1 = no problem; 5 = problematic). Safety evaluations included vaginal examinations and adverse event (AE) monitoring. Data were analyzed descriptively.Results: After three weeks, the median (min-max) overall acceptance score was 9.5 (5 - 10); insertion and removal scored 10 (8-10) and 9 (3-10), respectively. Median comfort scores ranged 8-10. The physician's ease-of-insertion/removal median score was 1 (1 - 5). Two participants discontinued due to AEs: inability to remove the ring and vaginal irritation.Conclusion: The MedRing demonstrated high user acceptability and ease of use, supporting its use as a personalized, self-controlled treatment device across a wide age range.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"945-952"},"PeriodicalIF":5.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146004862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical hurdles for curcumin and piperine nanoparticles in prostate cancer treatment: a bridge too far or a path to clinical reality? 姜黄素和胡椒碱纳米颗粒用于前列腺癌治疗的临床障碍：是桥梁过远还是通往临床现实的道路？

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-05-01 Epub Date: 2026-01-22 DOI: 10.1080/17425247.2026.2619094

Jibira Yakubu, Oya Tagit, Amit V Pandey

{"title":"Clinical hurdles for curcumin and piperine nanoparticles in prostate cancer treatment: a bridge too far or a path to clinical reality?","authors":"Jibira Yakubu, Oya Tagit, Amit V Pandey","doi":"10.1080/17425247.2026.2619094","DOIUrl":"10.1080/17425247.2026.2619094","url":null,"abstract":"Introduction: Prostate cancer (PC) treatment is limited by resistance mechanisms and cumulative toxicities, necessitating novel therapeutic strategies. While curcumin and piperine exhibit potent anticancer properties, their clinical utility is severely compromised by poor bioavailability and rapid metabolism.Areas covered: This review critically analyzes the preclinical and clinical landscape of curcumin and piperine nanoformulations (CPN) for the treatment of PC. We utilized PubMed and Scopus (2000-2025) to evaluate molecular mechanisms, focusing on CYP17A1 inhibition, PI3K/Akt/mTOR signaling, and ferroptosis. The report examines the physicochemical properties of nanocarriers, including PLGA and liposomes, and addresses translational barriers such as the heterogeneity of the Enhanced Permeability and Retention (EPR) effect, stromal density, and risks associated with piperine-mediated drug - drug interactions.Expert opinion: While nano-encapsulation enhances the therapeutic index of curcumin, clinical translation remains stalled by a reliance on passive targeting and insufficient manufacturing scalability. Future success depends on shifting from 'beaker' synthesis to microfluidic production (Quality by Design) and adopting active targeting (e.g. PSMA-directed delivery) to penetrate the prostate stroma. Without these strategic pivots and biomarker-driven trials, CPNs risk remaining an academic curiosity rather than evolving into a viable clinical intervention.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"781-796"},"PeriodicalIF":5.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical film-forming systems for antifungal delivery: emerging strategies and in-depth evaluation. 局部成膜系统用于抗真菌递送：新兴策略和深入评估。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-05-01 Epub Date: 2026-02-22 DOI: 10.1080/17425247.2026.2631774

Siddhi Rawool, Manigandan Thevar, Supriya Shidhaye, Mangal Nagarsenker

{"title":"Topical film-forming systems for antifungal delivery: emerging strategies and in-depth evaluation.","authors":"Siddhi Rawool, Manigandan Thevar, Supriya Shidhaye, Mangal Nagarsenker","doi":"10.1080/17425247.2026.2631774","DOIUrl":"10.1080/17425247.2026.2631774","url":null,"abstract":"Introduction: Topical film-forming systems (FFSs) are a promising approach for antifungal therapy. After application, the solvent evaporates, leaving a thin polymeric film on the skin. This film acts as a drug reservoir, increasing residence time, improving patient comfort, and offering greater convenience compared with conventional creams and gels.Areas covered: Examples of patented antifungal FFSs and available clinical trial data are included to illustrate translational potential. This review then outlines different types of FFSs such as sprays, solutions, gels, and emulgels. Evaluation methods, including mechanical strength, adhesion, substantivity, in vitro release testing (IVRT), in vitro permeation testing (IVPT) and antifungal activity, are also described. Searches of Google Scholar and PubMed were undertaken to gather the literature included in this review.Expert opinion: FFSs show superior benefits in treating superficial fungal infections by enhancing substantivity, providing sustained drug delivery, and improving adherence. Products such as single-application terbinafine films and novel nanocarrier - FFS hybrids demonstrate this potential. However, further standardized IVRT/IVPT clinical validation methods are needed to support wider adoption and ensure translation of laboratory findings into clinical outcomes.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"893-907"},"PeriodicalIF":5.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146204498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in mucoadhesive and mucus-penetrating materials, nano-formulations, and in situ gelling systems for nasal drug delivery. 鼻腔给药的黏附和黏液穿透材料、纳米配方和原位胶凝系统的研究进展。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-05-01 Epub Date: 2026-02-18 DOI: 10.1080/17425247.2026.2628612

Natalia N Porfiryeva, Rouslan I Moustafine, Vitaliy V Khutoryanskiy

{"title":"Advances in mucoadhesive and mucus-penetrating materials, nano-formulations, and in situ gelling systems for nasal drug delivery.","authors":"Natalia N Porfiryeva, Rouslan I Moustafine, Vitaliy V Khutoryanskiy","doi":"10.1080/17425247.2026.2628612","DOIUrl":"10.1080/17425247.2026.2628612","url":null,"abstract":"Introduction: Intranasal drug delivery is increasingly valued not only for local therapy but also as a noninvasive route that can bypass the blood - brain barrier, enabling rapid treatment of neurological and systemic diseases. However, mucociliary clearance and limited epithelial absorption often reduce residence time and bioavailability, creating a need for more effective formulation strategies. Mucoadhesive and mucus-penetrating systems are among the most promising approaches.Areas covered: This review summarizes nasal anatomical and physiological features that govern interactions between formulations and the mucosa. It overviews representative intranasal dosage forms (liquids, powders, gels, films, in situ gelling systems, and nano-formulations). Polymers used as mucoadhesive agents are classified into first- and second-generation materials, which enhance adhesion through hydrogen bonding, electrostatic interactions, or covalent attachment. The review also highlights polymers applied to nanoparticle surfaces to facilitate diffusion through mucus and improve epithelial access. Finally, methods to evaluate mucoadhesion and toxicity are outlined, including alternative in vitro and in vivo models.Expert opinion: Recent advances have expanded nasal delivery options, particularly for nose-to-brain targeting. Yet translation remains limited by insufficient validation, long-term safety uncertainties, and repeated-dose effects. Future progress requires balancing adhesion with penetration, robust toxicology, and integration of innovative polymers with optimized devices.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"797-822"},"PeriodicalIF":5.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146128085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic nanofibrous scaffolds in precision drug delivery: formulation design, challenges and regulatory frameworks. 治疗性纳米纤维支架在精确给药：配方设计，挑战和监管框架。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-05-01 Epub Date: 2026-01-20 DOI: 10.1080/17425247.2026.2619643

Mariam Majida Shokoya, Edina Szabó, Zsombor Kristóf Nagy, István Sebe, Romána Zelkó

{"title":"Therapeutic nanofibrous scaffolds in precision drug delivery: formulation design, challenges and regulatory frameworks.","authors":"Mariam Majida Shokoya, Edina Szabó, Zsombor Kristóf Nagy, István Sebe, Romána Zelkó","doi":"10.1080/17425247.2026.2619643","DOIUrl":"10.1080/17425247.2026.2619643","url":null,"abstract":"Introduction: Drug-loaded nanofibrous systems represent a breakthrough in drug delivery, overcoming limitations of conventional formulations. They demonstrate controlled morphology and flexibility across multiple administration routes, with versatility delivering small-molecule and biological drugs, and supporting diverse technological implementations. These platforms address unmet clinical needs in dissolution enhancement, drug stabilization, targeted delivery, thus enhancing bioavailability.Areas covered: The expert review critically evaluates formulation design innovations, scalable manufacturing technologies, and application-specific challenges across buccal, nasal, ophthalmic, transdermal, implantable and vaginal nanofibrous systems. It covers the regulatory framework and clinical status while addressing the gap between research and industrial implementation. It emphasizes the critical limitations, drawbacks, and manufacturing barriers that have prevented widespread clinical adoption, alongside strategies to overcome obstacles.Expert opinion: Nanofibrous drug delivery systems offer advantages in dissolution enhancement, biological protection, and patient-tailored administration. However, industrial implementation and regulatory acceptance remain constrained by scalable manufacturing, cost-effectiveness and regulatory harmonization. Despite promising preclinical results, no pharmaceutical drug-loaded nanofiber product has yet achieved FDA or EMA approval.Clinical translation requires process innovation, quality assurance, and demonstrated superiority, supported by artificial intelligence, digital sensors and 3D printing technologies. Over the next five years, nanofiber-based technologies are anticipated to drive innovation in patient-centered therapies.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"823-839"},"PeriodicalIF":5.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146000211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chitosan nanoparticles for brain targeted nose-to-brain drug delivery in neurodegenerative disease: a comprehensive exploration of advances, limitations and future prospects. 壳聚糖纳米颗粒用于神经退行性疾病的脑靶向鼻至脑药物递送：进展，局限性和未来前景的综合探索。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-05-01 Epub Date: 2026-01-29 DOI: 10.1080/17425247.2026.2619090

Mumtaz, Devika Unnithan, Hadiseh Hosseini, Javed Ali, Mohammad Ahmed Khan

{"title":"Chitosan nanoparticles for brain targeted nose-to-brain drug delivery in neurodegenerative disease: a comprehensive exploration of advances, limitations and future prospects.","authors":"Mumtaz, Devika Unnithan, Hadiseh Hosseini, Javed Ali, Mohammad Ahmed Khan","doi":"10.1080/17425247.2026.2619090","DOIUrl":"10.1080/17425247.2026.2619090","url":null,"abstract":"Introduction: Neurodegenerative diseases (NDDs), such as Alzheimer's and Parkinson's and epilepsy, cause irreversible nerve cell degradation, resulting in cognitive and motor decline. The blood-brain barrier (BBB) complicates treatment, limiting drug access and causing low bioavailability. Chitosan nanoparticles (CH-NPs) offer a promising solution for improving drug delivery to the brain due to their biocompatibility and ability to enhance intranasal delivery, potentially increasing therapeutic efficacy.Areas of coverage: The review discusses advancements in chitosan-based nanoparticle drug delivery systems for NDDs, highlighting literature from 2015 to 2025. It indicates that chitosan can improve drug uptake in the brain by up to ten times and emphasizes its potential for targeted central nervous system (CNS) delivery due to its unique properties. Additionally, intranasal delivery is a non-invasive method to bypass the BBB and enhance therapeutic precision.Expert opinion: CH-NPs effectively deliver therapeutics to the CNS, leveraging their mucoadhesive properties and biocompatibility to cross the BBB via intranasal delivery. This platform enhances drug uptake and retention in the brain, addressing challenges faced by traditional therapies for NDDs. Optimizing nanoparticle biomaterial properties and delivery methods could improve therapeutic precision and clinical outcomes.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"761-779"},"PeriodicalIF":5.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146047590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanistic and translational frontiers on "VEGF and TKI inhibitor axitinib": unfolding drug delivery approaches and opportunities in cancer therapy. “VEGF和TKI抑制剂阿西替尼”的机制和翻译前沿：在癌症治疗中展开药物传递途径和机会。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-05-01 Epub Date: 2026-02-24 DOI: 10.1080/17425247.2026.2635404

Divya Sharma, Shiv Kumar Prajapati, Sweta Acharya, Ankit Jain

{"title":"Mechanistic and translational frontiers on \"VEGF and TKI inhibitor axitinib\": unfolding drug delivery approaches and opportunities in cancer therapy.","authors":"Divya Sharma, Shiv Kumar Prajapati, Sweta Acharya, Ankit Jain","doi":"10.1080/17425247.2026.2635404","DOIUrl":"10.1080/17425247.2026.2635404","url":null,"abstract":"Introduction: Axitinib demonstrates significant promise in the field of oncology. It effectively inhibits vascular endothelial growth factor (VEGF)-mediated angiogenesis, endothelial proliferation, and tumor microvascular density. Axitinib exhibits reduced off-target kinase inhibition compared to first-generation tyrosine kinase inhibitors (TKIs), thereby minimizing broad-spectrum toxicity. However, axitinib's poor aqueous solubility, limited oral bioavailability, first-pass metabolism, and susceptibility to environmental degradation present key pharmacokinetic challenges in its translational application.Areas covered: This review integrates insights from pharmacology, clinical research, and patent literature, while delving into state-of-the-art formulation design paradigms, including lipid nanocarriers, polymeric formulations, stimuli-responsive formulations, and hydrogels. The rationale for such design paradigms is to improve solubility, controlled release, stability, and tumor targeting, thereby enhancing pharmacodynamics and ensuring a better safety profile. A literature search across major databases from 2000 to 2026 supported these findings.Expert opinion: Despite progress in targeted cancer treatment, sustained-release platforms enhance therapeutic potential while minimizing off-target effects. Studies are increasingly being conducted on axitinib combined with compatible anticancer agents after pharmacokinetic and safety considerations. These combinations may alter angiogenic signaling and delay the onset of resistance. As clinical priorities focus on minimizing toxicity, formulation innovations will be crucial to maximize the therapeutic potential of axitinib.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"919-943"},"PeriodicalIF":5.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent and future developments in inhaled formulations to overcome anti-bacterial drug resistance. 克服抗菌耐药的吸入制剂的最新和未来发展。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-05-01 Epub Date: 2026-02-11 DOI: 10.1080/17425247.2026.2631043

Nazrul Islam, Trudi Collet

{"title":"Recent and future developments in inhaled formulations to overcome anti-bacterial drug resistance.","authors":"Nazrul Islam, Trudi Collet","doi":"10.1080/17425247.2026.2631043","DOIUrl":"10.1080/17425247.2026.2631043","url":null,"abstract":"Introduction: Inhaled antibiotic delivery technology is considered an emerging method for overcoming continual challenges posed by resistant bacteria. It enables the delivery of highly localized drug concentrations, thereby reducing systemic exposure, whilst targeting infected cells to efficiently kill resistant bacteria.Areas covered: The clinical outcomes of inhaled antibiotic delivery strategies against resistant bacteria are limited. With a focus on preclinical and clinical outcomes, this review highlights recent advances in the development of inhaled antibiotic formulations. Further, it emphasizes the emerging strategies as a blueprint for future therapeutic options against resistant bacteria.Expert opinion: Inhaled antibiotic formulations represent one of the most promising avenues for overcoming antibacterial drug resistance. This is achieved by delivering high local doses of antibiotics directly to infected cells, which specifically targets biofilm/mucus and resistant pathogens. Although promising developments in inhaled antibacterials include proteins and peptides, liposomal and lipid‑based nano-carriers, combination therapies, phase therapy, and alveolar macrophage targeted delivery are progressing, some potential barriers such as mucus, biofilms, and bacterial resistance continue to impede clinical translation. As a result, real-world strategic priorities should be emphasized regarding the development of smart inhaled antibacterial formulations with clinical potential to overcome the ongoing barriers associated with antimicrobial-resistant bacteria.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"877-892"},"PeriodicalIF":5.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146151546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intravitreal implants for drug delivery: clinical efficacy, safety, and translational perspectives. 玻璃体内植入物用于药物传递：临床疗效、安全性和翻译观点。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-05-01 Epub Date: 2026-02-13 DOI: 10.1080/17425247.2026.2629545

Carolina Nunes da Silva, Thomas Toshio Inoue, Marina França Dias, Silvia Ligorio Fialho, Armando Silva-Cunha

{"title":"Intravitreal implants for drug delivery: clinical efficacy, safety, and translational perspectives.","authors":"Carolina Nunes da Silva, Thomas Toshio Inoue, Marina França Dias, Silvia Ligorio Fialho, Armando Silva-Cunha","doi":"10.1080/17425247.2026.2629545","DOIUrl":"10.1080/17425247.2026.2629545","url":null,"abstract":"Introduction: Chronic retinal disorders such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and noninfectious uveitis are among the leading causes of irreversible visual loss worldwide. Their management depends on repeated intravitreal injections of anti-VEGF agents or corticosteroids, which, despite proven efficacy, are associated with high treatment burden and cumulative risks. Sustained-release intravitreal drug delivery systems (DDSs) are effective strategies to prolong therapeutic activity, enhance bioavailability, minimize adverse events, and improve patient adherence.Areas covered: This review provides an overview of the evolution, clinical efficacy, and translational potential of intravitreal DDSs, from nonbiodegradable implants to biodegradable systems. Advances in polymeric design, hydrogels, in situ forming systems, and 3D-printed architecture, are discussed alongside emerging clinical candidates. Key formulation, preclinical, and regulatory barriers to clinical translation are also examined. Comprehensive search on PubMed, Scopus, Web of Science, ClinicalTrials.gov, and regulatory repositories was performed (data published up to December 2025).Expert opinion: Intravitreal DDSs are redefining ocular pharmacotherapy by offering prolonged, localized drug release. However, further innovation in polymer design, bioerodible materials, and sterilization methods is essential to balance safety, efficacy, and manufacturability. Integration of precision medicine and next-generation biomaterials will be key to achieving fully optimized, minimally invasive retinal therapies.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"841-859"},"PeriodicalIF":5.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146151557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0